Development of a symptom menu to facilitate Goal Attainment Scaling in adults with Down syndrome-associated Alzheimer's disease: a qualitative study to identify meaningful symptoms.
Alzheimer’s disease
Dementia
Down syndrome
Goal attainment scaling
Qualitative study
Symptoms
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
11 Jan 2021
11 Jan 2021
Historique:
received:
28
08
2020
accepted:
21
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
As life expectancy of people with Down syndrome (DS) increases, so does the risk of Alzheimer's disease (AD). Identifying symptoms and tracking disease progression is especially challenging whenever levels of function vary before the onset of dementia. Goal Attainment Scaling (GAS), an individualized patient-reported outcome, can aid in monitoring disease progression and treatment effectiveness in adults with DS. Here, with clinical input, a validated dementia symptom menu was revised to facilitate GAS in adults living with Down Syndrome-associated Alzheimer's disease (DS-AD). Four clinicians with expertise in DS-AD and ten caregivers of adults living with DS-AD participated in semi-structured interviews to review the menu. Each participant reviewed 9-15 goal areas to assess their clarity and comprehensiveness. Responses were systematically and independently coded by two researchers as 'clear', 'modify', 'remove' or 'new'. Caregivers were encouraged to suggest additional items and recommend changes to clarify items. Median caregiver age was 65 years (range 54-77). Most were female (9/10) with ≥15 years of education (10/10). Adults with DS-AD had a median age of 58 years (range 52-61) and either a formal diagnosis (6/10) or clinical suspicion (4/10) of dementia. The initial symptom menu consisted of 67 symptoms each with 2-12 descriptors (589 total). The clinicians' adaptation yielded 58 symptoms each with 4-17 descriptors (580 total). Of these 580 descriptors, caregivers identified 37 (6%) as unclear; these were reworded, and one goal area (4 descriptors) was removed. A further 47 descriptors and one goal area were added to include caregiver-identified concepts. The final menu contained 58 goal areas, each with 7-17 descriptors (623 total). A comprehensive symptom menu for adults living with DS-AD was developed to facilitate GAS. Incorporating expert clinician opinion and input from caregivers of adults with DS-AD identified meaningful items that incorporate patient/caregiver perspectives.
Sections du résumé
BACKGROUND
BACKGROUND
As life expectancy of people with Down syndrome (DS) increases, so does the risk of Alzheimer's disease (AD). Identifying symptoms and tracking disease progression is especially challenging whenever levels of function vary before the onset of dementia. Goal Attainment Scaling (GAS), an individualized patient-reported outcome, can aid in monitoring disease progression and treatment effectiveness in adults with DS. Here, with clinical input, a validated dementia symptom menu was revised to facilitate GAS in adults living with Down Syndrome-associated Alzheimer's disease (DS-AD).
METHODS
METHODS
Four clinicians with expertise in DS-AD and ten caregivers of adults living with DS-AD participated in semi-structured interviews to review the menu. Each participant reviewed 9-15 goal areas to assess their clarity and comprehensiveness. Responses were systematically and independently coded by two researchers as 'clear', 'modify', 'remove' or 'new'. Caregivers were encouraged to suggest additional items and recommend changes to clarify items.
RESULTS
RESULTS
Median caregiver age was 65 years (range 54-77). Most were female (9/10) with ≥15 years of education (10/10). Adults with DS-AD had a median age of 58 years (range 52-61) and either a formal diagnosis (6/10) or clinical suspicion (4/10) of dementia. The initial symptom menu consisted of 67 symptoms each with 2-12 descriptors (589 total). The clinicians' adaptation yielded 58 symptoms each with 4-17 descriptors (580 total). Of these 580 descriptors, caregivers identified 37 (6%) as unclear; these were reworded, and one goal area (4 descriptors) was removed. A further 47 descriptors and one goal area were added to include caregiver-identified concepts. The final menu contained 58 goal areas, each with 7-17 descriptors (623 total).
CONCLUSIONS
CONCLUSIONS
A comprehensive symptom menu for adults living with DS-AD was developed to facilitate GAS. Incorporating expert clinician opinion and input from caregivers of adults with DS-AD identified meaningful items that incorporate patient/caregiver perspectives.
Identifiants
pubmed: 33427993
doi: 10.1186/s41687-020-00278-7
pii: 10.1186/s41687-020-00278-7
pmc: PMC7801557
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Références
J Am Geriatr Soc. 1992 Jun;40(6):574-8
pubmed: 1587973
Community Ment Health J. 1968 Dec;4(6):443-53
pubmed: 24185570
J Med Internet Res. 2013 Aug 07;15(8):e145
pubmed: 23924608
Arch Phys Med Rehabil. 2007 Jan;88(1):1-10
pubmed: 17207668
PLoS One. 2016 May 06;11(5):e0154596
pubmed: 27153191
Neurology. 1994 Dec;44(12):2315-21
pubmed: 7991118
J Intellect Disabil Res. 2006 Oct;50(Pt 10):768-77
pubmed: 16961706
J Intellect Disabil Res. 2014 Jan;58(1):61-70
pubmed: 23902161
SAGE Open Med. 2019 Jan 02;7:2050312118822927
pubmed: 30637106
Am J Med Genet A. 2017 Nov;173(11):3058-3066
pubmed: 28857390
Lancet Neurol. 2016 May;15(6):622-36
pubmed: 27302127
J Med Internet Res. 2019 Jun 28;21(6):e13360
pubmed: 31254339
J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):500-7
pubmed: 12397141
J Gerontol A Biol Sci Med Sci. 1999 Dec;54(12):M641-7
pubmed: 10647971
Alzheimers Dement. 2015 Jun;11(6):700-9
pubmed: 25510383
Neuropsychol Rev. 2017 Mar;27(1):31-45
pubmed: 28289920
Int J Geriatr Psychiatry. 2020 Jun;35(6):650-661
pubmed: 32100307
Neurosci Biobehav Rev. 2017 Dec;83:713-720
pubmed: 28235545
Int Psychogeriatr. 2019 Nov;31(11):1635-1641
pubmed: 30698122
Am J Alzheimers Dis Other Demen. 2018 Aug;33(5):301-308
pubmed: 29660988
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
Alzheimers Dement. 2017 Oct;13(10):1098-1106
pubmed: 28341540
J Intellect Disabil Res. 2018 Jul;62(7):617-624
pubmed: 29781149
Child Care Health Dev. 2008 Jul;34(4):521-9
pubmed: 19154553
CMAJ. 2006 Apr 11;174(8):1099-105
pubmed: 16554498
Alzheimers Dement (N Y). 2018 Dec 13;4:703-713
pubmed: 30581976
J Intellect Disabil Res. 2007 Sep;51(Pt 9):726-39
pubmed: 17845241
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
Am J Phys Med Rehabil. 1994 Feb;73(1):10-4
pubmed: 8305175
Am J Alzheimers Dis Other Demen. 2018 Jun;33(4):253-262
pubmed: 29504408
Haemophilia. 2018 Jul;24(4):e199-e206
pubmed: 29626387
Int Psychogeriatr. 2017 Jun;29(6):959-966
pubmed: 28274302
Pilot Feasibility Stud. 2018 Dec 12;4:184
pubmed: 30564435
Disabil Rehabil. 2012;34(20):1716-26
pubmed: 22397694
Int J Geriatr Psychiatry. 2017 Dec;32(12):1257-1263
pubmed: 27699865
Can J Neurol Sci. 2013 Jul;40(4):564-71
pubmed: 23786741
J Am Geriatr Soc. 2018 Nov;66(11):2120-2127
pubmed: 30298901
Health Expect. 2009 Sep;12(3):288-300
pubmed: 19754692
Nat Rev Neurol. 2019 Mar;15(3):135-147
pubmed: 30733618
Arch Phys Med Rehabil. 2008 Apr;89(4):652-9
pubmed: 18373995
J Elder Abuse Negl. 2018 Mar;30(3):209-222
pubmed: 29601281
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Am J Intellect Dev Disabil. 2017 May;122(3):247-281
pubmed: 28452584
J Med Internet Res. 2012 Mar 12;14(2):e42
pubmed: 22411293
Neurology. 1999 Jul 22;53(2):331-6
pubmed: 10430422
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Arch Neurol. 1989 Aug;46(8):849-53
pubmed: 2527024
Clin Rehabil. 2009 Apr;23(4):362-70
pubmed: 19179355
Clin Pharmacol Ther. 2010 Oct;88(4):446-9
pubmed: 20856240
Gerontologist. 1998 Dec;38(6):735-42
pubmed: 9868853
Age Ageing. 1999 May;28(3):275-81
pubmed: 10475864
PLoS One. 2016 May 12;11(5):e0153917
pubmed: 27171413
BMC Geriatr. 2007 Jul 03;7:16
pubmed: 17605827